Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Vertex Pharmaceuticals Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of acute and chronic pain.
Haisco Pharmaceutical Group Co. Ltd. has disclosed new tetrahydrofuran derivatives acting as sodium channel protein type 10 subunit alpha (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro (UFRJ) have jointly patented new sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.
Haisco Pharmaceutical Group Co. Ltd. has discovered sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Several Grünenthal GmbH patents describe sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain.
Humanwell Healthcare (Group) Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Shanghai Huilun Pharmaceutical Co. Ltd. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, multiple sclerosis, Charcot-Marie-Tooth disease, urinary incontinence, cough and arrhythmia.
